Cancer vaccine NY-ESO-1 - Dendreon
Alternative Names: APC80NY; Cancer vaccine NY-ESO - DendreonLatest Information Update: 10 Oct 2021
At a glance
- Originator Dendreon Corporation
- Class Cancer vaccines; Dendritic cell vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Nov 2006 Preclinical development is still ongoing for Cancer in USA
- 12 Oct 2004 This vaccine is still in active development
- 24 Sep 2002 This vaccine is still in active development